论文部分内容阅读
目的:探讨新型靶向治疗药物厄洛替尼对人卵巢癌细胞株SKOV3的作用。方法:体外培养人卵巢癌细胞株SKOV-3,采用MTT(噻唑蓝)检测不同浓度(0,10,15,20,40,50,60,70,80μmol/L)的厄洛替尼作用不同时间(24,48,72h)的细胞增殖活力变化,应用流式细胞仪对不同药物浓度作用后细胞凋亡、细胞周期情况进行分析。结果:厄洛替尼对人卵巢癌SKOV3细胞有抑制作用,且呈现时间及剂量依赖性。对照组与实验组比较,差异有统计学意义。随着药物浓度的增加,正常细胞逐渐减少,早期凋亡及晚期凋亡细胞呈现上升趋势,不同浓度组间比较有差异,差异有统计学意义。不同浓度的厄洛替尼作用于SKOV-3后,各浓度组相比较,随着药物浓度的增加,G0/G1期细胞数量明显增加,S期及G2/M期细胞数量呈减少趋势,差异有统计学意义。结论:厄洛替尼具有明显抑制卵巢癌细胞的增殖活力,促进细胞凋亡的作用,将SK0V3细胞周期阻滞于G0/G1期。其在卵巢癌的治疗中,可能具有一定的临床意义。
Objective: To investigate the effect of erlotinib on human ovarian cancer cell line SKOV3. Methods: Human ovarian cancer cell line SKOV-3 was cultured in vitro. The effects of erlotinib on different concentrations (0, 10, 15, 20, 40, 50, 60, 70 and 80 μmol / L) Time (24,48,72h) changes in cell proliferation, the use of flow cytometry of different drug concentrations after apoptosis, cell cycle analysis. Results: Erlotinib inhibited human ovarian cancer cell line SKOV3 in a time-and dose-dependent manner. The control group and experimental group, the difference was statistically significant. With the increase of drug concentration, the number of normal cells gradually decreased, the number of early apoptotic cells and late apoptotic cells showed an upward trend, and there were significant differences between different concentration groups. The difference was statistically significant. After treated with different concentrations of erlotinib, the number of cells in G0 / G1 phase increased significantly and the number of cells in S phase and G2 / M phase decreased with the increase of drug concentration in SKOV-3 cells. The difference was statistically significant There is statistical significance. CONCLUSION: Erlotinib can significantly inhibit the proliferation and promote the apoptosis of ovarian cancer cells, and block the SKOV3 cell cycle in G0 / G1 phase. Its treatment of ovarian cancer may have some clinical significance.